Drug intelligence / Profile preview

VS-15

Development stage: Unknown
Lead developer: VascuStim
Modality: Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Topical, Implant

Overview

VS-15 is a multi-component regenerative medicine composition developed by VascuStim (a unit of Leonhardt Ventures). It is designed for severe cases of vascular and organ regeneration and healing. The composition combines stem cells, growth factors, selected exosomes, selected microRNAs, selected alkaloids, a nutrient hydrogel, and a matrix to promote tissue repair, peripheral vascular circulation, and healing. It is typically used in combination with bioelectric signaling and amniotic fluid membranes for advanced regenerative therapies.

Beyond the preview

Go deeper on VS-15.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VS-15.

Explore the full profile